Researchers at JAIST, Daiichi Sankyo, and University of Tsukuba developed a bacterial consortium therapy, AUN, demonstrating complete tumor remission in both immunocompetent and immunocompromised mice. The treatment uses two bacteria inducing selective intratumoral thrombosis and necrosis without triggering systemic toxicity. This immunotherapy bypasses the need for a functional immune system, potentially benefiting patients with compromised immunity where current immunotherapies fall short.